Skip to content

Oxford BioTherapeutics

Sector:
Biotechnology
Invested in:
Calculus EISs, Calculus VCT

Oxford BioTherapeutics (OBT) is a clinical stage oncology company committed to the discovery and development of novel therapies for various cancer types

In February 2020, the company completed a £3.7m investment round from existing shareholders, which will be used to extend the current cash runway, allowing the continued development of therapeutics leads, the success of which is key to management’s focus of preparing for a potential exit in 2021.

Rationale

OBT has a strong pipeline of immune-oncology (IO) therapies, which are used to re-engage and recruit the body’s immune system to attack cancer cells, therefore providing targeted treatment strategies to patients most in need, including those who have failed to respond to conventional treatments. OBT has agreed multiple development deals including a collaboration agreement with Italy’s largest pharmaceutical company, The Menarini Group, which is fully funding the development of two clinical programmes through to completion of Phase II. The first program centres on Acute Myeloid Leukaemia (AML), with the second focused across a number of indications including breast, bladder and non-Hodgkin’s lymphoma. Additionally, OBT has partnered with German pharmaceutical company, Boehringer Ingelheim, for two pre-clinical stage programs. OBT has two unique development platforms to support the discovery of novel therapeutics. The OBT IO Discovery platform, which is one of the largest proteomics databases in the world, provides unique insight into immuno-oncology mechanisms-of-action. The second platform comprises a library of tumour cultures to enable rapid testing in tumours.

The funds from Calculus will primarily be used to prepare the IO pre-clinical pipeline for clinical development as well as funding the development of further therapeutic leads.

Latest News

Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued

Oxford BioTherapeutics establishes research collaboration with global cell therapy leader, Kite

Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued

Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance

Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued

Oxford BioTherapeutics Initiates U.S. Phase I Clinical Trial

Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid tumours. Dose-escalation is the first part of the Phase I program that includes two U.S. … Continued

Other Biotechnology Investments

Invizius

Invizius is a biotechnology company developing treatments to suppress unwanted innate immune responses

Arecor

Arecor is a life sciences company focused on developing superior biopharmaceutical products via the application of its patented Arestat™ formulation technology platform

C4X Discovery

C4X Discovery is a drug discovery and development company

Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms

Browse by sector

Callback Request

Please enter a phone number or email address where we can contact you
Consent(Required)

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

This site uses cookies as described in our Cookie Policy. By continuing to browse this site you are agreeing to our use of cookies.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

This site uses cookies as described in our Cookie Policy. By continuing to browse this site you are agreeing to our use of cookies.

I have read and understood this important information